Stocks expected to have increasing option volume: LLY SCS DRI RAD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Eli Lilly (LLY) PT Raised to 'Street High' $300 at Cantor Fitzgerald
June 24, 2021 9:10 AM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to a "Street High" $300.00 (from $245.00) while maintaining an Overweight rating after the FDA has granted its Alzheimer's disease drug donanemab Breakthrough Therapy Designation.
... MoreEli Lilly (LLY) PT Raised to $250 at Mizuho Securities as Donanemab Granted Breakthrough Therapy Designation
June 24, 2021 8:47 AM EDTMizuho Securities analyst Vamil Divan raised the price target on Eli Lilly (NYSE: LLY) to $250.00 (from $217.00) while maintaining a Buy rating.
The analyst commented, "Lilly has answered one of the most pressing questions in our coverage, announcing the FDA has granted its Alzheimer's disease drug... More



